Allegro Opthalmics, LLC Signs Licensing Deal With Senju Pharmaceutical Co.

Allegro Ophthalmics, LLC

Represented Allegro Ophthalmic, LLC in a licensing deal with Senju Pharmaceutical Co., Ltd. to develop and market Allegro's Integrin Peptide Therapy in Japan. Read the press release.

Integrin Peptide Therapy, a novel approach to treating vascular eye diseases, utilizes an oligopeptide discovered by Allegro’s founders in collaboration with Caltech.